Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 immunogenicity and safety study of MMR vaccine with new mumps component RS12 in young children
IRCT201206304412N6Phase 2Completed
- Sponsor
- Razi Vaccine and Serum Research Institute
- Start
- Aug 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of measles, mumps, and rubella vaccine in measles, mumps and rubella, sponsored by Razi Vaccine and Serum Research Institute. Primary endpoints: Immunogenicity and Safety. Started Aug 2015; status: completed.
02
Drugs
measles, mumps, and rubella vaccine
03
Conditions
measlesmumpsrubella
Beyond the preview
Go deeper on IRCT201206304412N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201206304412N6.